Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 48 % of short-term debt in 2025; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
DR. I. Vanhoutte, radiotherapie-oncologie from Gent, company number BE0683757552, closed financial year 2025 with a result of € 713,360 after tax. For that financial year DR. I. Vanhoutte, radiotherapie-oncologie recorded a gross margin of € 1.1 million and equity of € 18,550. Compared with financial year 2024, the result moved from € 253,046 to € 713,360. Profitable, and profit is growing. The buffer shrank hard: equity is 97 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 18,550
▼ 97% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 713,360
▲ 182% vs 2024
Profit after tax over the fiscal year.
€ 168,044
▼ 8% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1.3 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 216,340
▲ 187% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 737
▲ € 662 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 25,952
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 184,998 | € 222,203 | € 400,597 | € 1,058,562 | ▲ 164% |
| Profit after taxes | € 110,136 | € 126,149 | € 253,046 | € 713,360 | ▲ 182% |
| Equity | € 476,445 | € 452,594 | € 585,640 | € 18,550 | ▼ 97% |
| Total debts | € 96,159 | € 19,545 | € 10,636 | € 750,209 | ▲ € 739,573 |
| Cash | € 90,161 | € 31,670 | € 182,483 | € 168,044 | ▼ 8% |
| Retained profit | € 457,895 | € 434,044 | € 567,090 | € 0 | ▼ 100% |
| Dividend | € 100,000 | € 150,000 | € 120,000 | € 1,280,451 | ▲ € 1.2 million |
| Balance sheet total | € 572,604 | € 472,139 | € 596,276 | € 768,759 | ▲ 29% |
Key figures of DR. I. Vanhoutte, radiotherapie-oncologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to DR. I. Vanhoutte, radiotherapie-oncologie?
What happened at DR. I. Vanhoutte, radiotherapie-oncologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 713,360 (▲ 182% vs 2024). Source: NBB ↗
- New establishment in Gent. KBO
- New establishment in Gent. KBO
- Ilse Vanhoutte became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 110,136 profit in 2022 to € 713,360 profit in 2025.
Paid € 381,797 in corporate taxes since 2022.
Best year ever: 2025, with € 713,360 profit.
Paid out € 1.7 million in dividends to the owners in total.
Management
Behind DR. I. Vanhoutte, radiotherapie-oncologie is Ilse Vanhoutte.
Directors
According to the 2025 annual accounts
Ilse Vanhoutte
Director
since 2017
Establishments
Establishment units
Physical locations of this company
De Pintelaan 337
9000 Gent
Groenebriel 1
9000 Gent
Active since 26 October 2017
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0683.757.552
- VAT number
- BE 0683.757.552
- Registered office
- De Pintelaan 337, 9000 Gent
- Names & denominations
- DR. I. Vanhoutte, radiotherapie-oncologie
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 October 2017
- Peppol
- Not registered